It is time to implement molecular classification in endometrial cancer

Area of Science:

• Oncology
• Gynecologic Oncology
• Cancer Genomics

Background:

• Established prognostic factors for endometrial cancer (EC), including FIGO staging, grading, and molecular classification, have limitations in predicting patient outcomes and recurrence.
• While molecular classification has improved risk assessment and adjuvant treatment decisions for EC, it does not fully explain variations in recurrence patterns.

Purpose of the Study:

• To critically evaluate the limitations of current molecular classification in endometrial cancer (EC) management.
• To highlight emerging innovative strategies and research in EC that show potential for improved clinical impact.

Main Methods:

• Review of current literature on endometrial cancer (EC) risk stratification and molecular classification.
• Analysis of studies investigating novel biomarkers and prognostic factors in EC.
• Synthesis of evidence regarding the shortcomings of existing EC classification systems.

Main Results:

• Existing prognostic factors, including molecular subtypes, do not adequately predict EC recurrence profiles.
• Current EC guidelines lack comprehensive evidence for advanced risk stratification.
• Innovative research suggests potential for new molecular markers and integrated approaches to enhance EC risk assessment.

Conclusions:

• Molecular classification alone is insufficient for comprehensive endometrial cancer (EC) management and risk prediction.
• Further research and integration of novel biomarkers are crucial for refining EC patient stratification and treatment strategies.
• There is a need to update EC guidelines with evidence from innovative studies to improve patient outcomes.